Waters Corp Dossier
Qualitative Analysis
Business overview
Waters Corporation (NYSE: WAT) is a global leader in life sciences, diagnostics, and specialty measurement technologies. Headquartered in Milford, Massachusetts, the company designs, manufactures, sells, and services high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), mass spectrometry (MS), and thermal analysis systems. These analytical workflow solutions are critical in regulated, high-volume testing environments, primarily serving the pharmaceutical, biotechnology, industrial, academic, and government sectors. In early 2026, Waters completed a transformative $16.8 billion acquisition of Becton, Dickinson and Company's (BD) Biosciences and Diagnostic Solutions (BDS) business. This transaction significantly expanded Waters' addressable market, adding advanced cellular and molecular diagnostics, flow cytometry, and clinical microbiology capabilities to its core portfolio.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Integrating the newly acquired $17.5 billion Biosciences & Diagnostic Solutions businesses from Becton, Dickinson and Company to create a scaled, diversified global leader in life sciences and diagnostics.
Expected impact: Expected to expand the addressable market into biosciences and advanced diagnostics, with the acquired businesses expected to generate $3.035 billion of reported revenue in 2026, incorporating $15 million in expected revenue synergies.
Pushing migration programs to the Alliance iS HPLC and ACQUITY Premier/Arc Premier platforms to modernize installed bases in North America and Europe.
Expected impact: Aims to convert instrument replacements into expanded service contracts, improve attach rates in regulated labs, and expand the recurring revenue mix.
Initiating a comprehensive enterprise-wide ERP implementation to streamline global operations and support the newly integrated business divisions.
Expected impact: Aims to improve operational efficiency, data governance, and supply chain integration across the reorganized Analytical & Materials, Biosciences, and Advanced Diagnostics divisions.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To combine Waters' chemistry, physics, and mass spectrometry expertise with BD's biology, flow cytometry, and molecular diagnostics capabilities, creating a scaled life-science tools and diagnostics player with approximately 16,000 employees.
Financial impact: Contributed $520 million of reported revenue in Q1 2026 (exceeding guidance by $40 million). Expected to generate approximately $3.035 billion of reported revenue in 2026 on an owned-period basis, with $55 million in cost synergies and $50 million in revenue synergies targeted for the year.
To acquire specialized imaging technologies for particle analysis in therapeutic products, bringing Halo's Aura platform to complement Waters' existing Wyatt Technology portfolio and enhance capabilities in cell, protein, and gene therapies.
Financial impact: Expected to have a negligible impact on Waters' income statement over the first 12 months post-acquisition.
Strategic Partnerships
Combines Waters' HPLC/UPLC systems and Empower chromatography data software with SOTAX's dissolution testing and automated sample preparation systems to provide integrated, efficient workflows for pharmaceutical QA/QC.
Terms: Not disclosed
A long-standing collaboration of over 25 years delivering bidirectional integration between LabWare LIMS/ELN and Waters Empower Chromatography Data System to automate sample worklists and eliminate manual data entry errors.
Terms: Not disclosed